Vaxcyte Mourns the Sudden Passing of Board Member and Biopharmaceutical Industry Leader Michael Kamarck, Ph.D.
SAN CARLOS, Calif., July 6, 2023 -- Vaxcyte, Inc. (Nasdaq: PCVX) today issued the following statement on the sudden passing of Michael E. Kamarck, Ph.D., a member of the Vaxcyte Board of Directors.
“We are deeply saddened by the sudden passing of Dr. Michael Kamarck, a trusted and esteemed leader, advisor and colleague. He was a luminary in the biopharmaceutical industry, with long-standing, major contributions in vaccine and therapeutic product development and manufacturing that spanned over four decades. Mike’s desire to improve the lives of people around the word was evident through this commitment to public health and his support of companies large and small, on which he left a lasting mark. His compassionate nature extended far beyond his work as a beloved husband, father, grandfather and friend. We extend our deepest condolences to his family and all those he impacted throughout his life. Mike’s influence will always be felt within our industry, and he will be profoundly missed.”
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Jennifer Zibuda, Senior Director, Investor Relations
Janet Graesser, Vice President, Corporate Communications and Investor Relations